Literature DB >> 17325269

Gray matter involvement in multiple sclerosis.

Istvan Pirko1, Claudia F Lucchinetti, Subramaniam Sriram, Rohit Bakshi.   

Abstract

Gray matter (GM) involvement is detected even in the earliest stages of multiple sclerosis (MS), and GM atrophy occurs at a faster rate than white matter (WM) atrophy early in the disease course. Studies published to date establish that 1) GM involvement and in particular cortical demyelination can be extensive in MS; 2) GM pathology may occur in part independently of WM lesion formation; 3) a primarily GM-related process may be the earliest manifestation of MS; 4) GM involvement is associated with physical disability, fatigue, and cognitive impairment in MS; and 5) GM disease might help explain the observed dissociation between markers of inflammatory demyelination (relapses, WM gadolinium enhancement, WM lesion burden) and disease progression. It remains likely that GM damage is related to WM damage. However, continued studies of GM pathology as well as neuronal and axonal involvement in MS and related experimental models are necessary to better understand the etiology and pathogenesis of the degenerative components.

Entities:  

Mesh:

Year:  2007        PMID: 17325269     DOI: 10.1212/01.wnl.0000250267.85698.7a

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  112 in total

1.  Quantitative MR imaging of two-pool magnetization transfer model parameters in myelin mutant shaking pup.

Authors:  Alexey Samsonov; Andrew L Alexander; Pouria Mossahebi; Yu-Chien Wu; Ian D Duncan; Aaron S Field
Journal:  Neuroimage       Date:  2012-06-01       Impact factor: 6.556

2.  Theiler's virus infection: Pathophysiology of demyelination and neurodegeneration.

Authors:  Fumitaka Sato; Hiroki Tanaka; Faris Hasanovic; Ikuo Tsunoda
Journal:  Pathophysiology       Date:  2011-02

3.  In vivo evidence of disseminated subpial T2* signal changes in multiple sclerosis at 7 T: a surface-based analysis.

Authors:  J Cohen-Adad; T Benner; D Greve; R P Kinkel; A Radding; B Fischl; B R Rosen; C Mainero
Journal:  Neuroimage       Date:  2011-04-13       Impact factor: 6.556

4.  Gray matter pathology in MS: a 3-year longitudinal study in a pediatric population.

Authors:  M Calabrese; D Seppi; C Romualdi; F Rinaldi; S Alessio; P Perini; P Gallo
Journal:  AJNR Am J Neuroradiol       Date:  2012-03-15       Impact factor: 3.825

5.  Gradient echo plural contrast imaging--signal model and derived contrasts: T2*, T1, phase, SWI, T1f, FST2*and T2*-SWI.

Authors:  Jie Luo; Bharathi D Jagadeesan; Anne H Cross; Dmitriy A Yablonskiy
Journal:  Neuroimage       Date:  2012-01-28       Impact factor: 6.556

Review 6.  Grey matter lesions in MS: from histology to clinical implications.

Authors:  Massimiliano Calabrese; Alice Favaretto; Valeria Martini; Paolo Gallo
Journal:  Prion       Date:  2012-10-23       Impact factor: 3.931

7.  In vivo detection of connectivity between cortical and white matter lesions in early MS.

Authors:  Jan-Mendelt Tillema; Stephen D Weigand; Jay Mandrekar; Yunhong Shu; Claudia F Lucchinetti; Istvan Pirko; John D Port
Journal:  Mult Scler       Date:  2016-10-03       Impact factor: 6.312

8.  Optimizing 3D FLAIR to detect MS lesions: pushing past factory settings for precise results.

Authors:  Augustin Lecler; C Bouzad; R Deschamps; F Maizeroi; J C Sadik; A Gueguen; O Gout; H Picard; J Savatovsky
Journal:  J Neurol       Date:  2019-08-01       Impact factor: 4.849

9.  Resveratrol exacerbates both autoimmune and viral models of multiple sclerosis.

Authors:  Fumitaka Sato; Nicholas E Martinez; Maira Shahid; John W Rose; Noel G Carlson; Ikuo Tsunoda
Journal:  Am J Pathol       Date:  2013-10-01       Impact factor: 4.307

10.  The effect of daclizumab on brain atrophy in relapsing-remitting multiple sclerosis.

Authors:  Isabela T Borges; Colin D Shea; Joan Ohayon; Blake C Jones; Roger D Stone; John Ostuni; Navid Shiee; Henry McFarland; Bibiana Bielekova; Daniel S Reich
Journal:  Mult Scler Relat Disord       Date:  2013-04-01       Impact factor: 4.339

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.